Legend Biotech Corp. (LEGN) PT Raised to $76 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LEGN Hot Sheet
Price: $19.27 +1.96%
Rating Summary:
16 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
16 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
UBS analyst Ashwani Verma raised the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $76.00 (from $66.00) while maintaining a Buy rating.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Graco Inc. (GGG) PT Lowered to $80 at DA Davidson
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
